SOTIO wins dual FDA designations for ADC SOT106 in sarcoma
SOTIO Biotech has received two FDA designations for its investigational antibody-drug conjugate SOT106, targeting leucine-rich repeat-containing 15 (LRRC15) across multiple sarcoma subtypes. The Prague and Basel-based company said the FDA granted Fast Track Designation for osteosarcoma and Orphan Drug Designation for soft tissue sarcoma (STS), adding to designations the programme already held in each indication. A first-in-human clinical trial is expected to begin before the end of 2026.
SOT106 is engineered to bind selectively to LRRC15, a cell-surface protein expressed broadly across several sarcoma subtypes and validated as a clinically relevant target. The ADC pairs SOTIO's proprietary LRRC15-targeting antibody with LigaChem Biosciences' ConjuAll conjugation technology and a beta-glucuronidase-cleavable linker, designed to remain stable in systemic circulation and release cytotoxic payload selectively within the tumour microenvironment. Preclinical work in patient-derived xenograft models of both osteosarcoma and STS showed potent anti-tumour activity alongside what the company characterised as a favourable tolerability and therapeutic-index profile.
Regulatory context
Fast Track and Orphan Drug designations are procedural tools rather than efficacy endorsements, but they carry real development advantages. Fast Track status enables rolling review of marketing applications and more frequent FDA interaction, which can compress development timelines in an indication where regulatory dialogue is otherwise scheduled around submission milestones. Orphan Drug status, applicable to diseases affecting fewer than 200,000 people in the United States, provides seven years of market exclusivity post-approval, fee waivers, and tax credits on clinical trial costs. Sarcoma, a heterogeneous family of mesenchymal tumours, qualifies comfortably: osteosarcoma and STS each represent rare, high-unmet-need populations where standard-of-care options have changed little in decades.
Chief executive Radek Spisek said the designations reflect "growing momentum" behind SOTIO's ADC portfolio and underscored the lack of targeted options available to sarcoma patients today.
Competitive landscape
The ADC sector has attracted substantial investment and deal-making over the past two years, driven partly by high-profile licensing transactions and clinical successes in breast and urothelial cancer. Activity is now broadening into rarer solid tumours, where ADCs can exploit tumour-specific antigen expression patterns that are less amenable to checkpoint inhibitor strategies. LRRC15 as a target is at an earlier stage of clinical validation than HER2 or TROP-2, meaning SOT106 enters a relatively uncrowded field, though that also means the clinical proof-of-concept bar remains to be cleared in humans.
SOTIO's broader pipeline includes SOT109, a separate ADC currently in Phase 1/2 for colorectal cancer, and SOT201, a PD-1-targeting immunocytokine in the Phase 1 VICTORIA-01 study. The company is privately held through the PPF Group and has not disclosed funding quantum or development cost estimates for the SOT106 programme.
Investors and oncology specialists will be watching the first-in-human data closely. Key readouts will include the recommended Phase 2 dose, the safety and tolerability profile in patients, and early signals of anti-tumour activity. If early data support the preclinical therapeutic-index findings, SOT106 could become a meaningful entry in a sarcoma space that has seen very limited targeted-therapy approvals to date.